Longevity
Semaglutide reduced heart and liver damage in animals without weight loss
By Life and Health Today Staff, . Life and Health Today.
Semaglutide, the active ingredient in Ozempic and Wegovy, did something researchers did not expect in a new animal study: it improved heart and liver health without meaningfully reducing body weight. The findings, published in the European Heart Journal, raise a question that matters for anyone following GLP-1 research closely. Are the cardiac benefits of these drugs really just a side effect of losing weight, or is something else happening in the tissue itself?
The study tested that question directly in two preclinical models, meaning no human data was generated. Researchers used male ZSF1 Obese rats, with 12 animals per group, and female Göttingen minipigs engineered to develop a condition called heart failure with preserved ejection fraction, or HFpEF. HFpEF is a form of heart failure in which the heart muscle stiffens and struggles to fill properly between beats, even though it still pumps with normal force. It is common in people with obesity and metabolic disease, and it currently has few effective treatments.
The researchers gave semaglutide at doses they had specifically calibrated not to cause significant weight loss, so that any benefits observed could not be attributed to the animals getting lighter. In the rats, diastolic function, which is the heart's ability to relax and fill, improved substantially: left ventricular end-diastolic pressure, a measure of how hard the heart has to work to fill, fell by roughly 60 percent. Cardiac hypertrophy, meaning abnormal thickening of the heart muscle, was reduced by roughly 30 percent. Scarring of heart tissue and fat deposits within the heart also decreased, according to the European Heart Journal report.
The minipig results tracked in the same direction. In animals where HFpEF was already established before treatment began, semaglutide reversed diastolic dysfunction and reduced fat deposits inside the heart muscle, around the heart, and in the liver. Notably, it reversed what the researchers described as "advanced hepatic bridging fibrosis," a serious stage of liver scarring, without changing subcutaneous fat or total body weight.
To understand the molecular mechanism, the research team ran multi-omics analyses on rat heart tissue, combining plasma proteomics, single-cell RNA sequencing, and tissue proteomics. These techniques map gene activity and protein levels across thousands of individual cells simultaneously. The analyses pointed to suppression of signals that drive fibrosis and hypertrophy, alongside increased activity in pathways that break down branched-chain amino acids and fatty acids inside heart muscle cells. Whether those same pathways are active in human heart tissue is not established.
What this study cannot tell you is whether any of this translates to people. Both animal models are designed to mimic human HFpEF, and the researchers noted that the consistency of results across two different species, one rodent and one closer in physiology to humans, adds some weight to the findings. But the authors were explicit: future work is needed to define what dose in humans would be equivalent to the non-weight-loss doses used here, and to confirm that GLP-1 receptors, the molecular targets semaglutide acts on, are actually engaged in human cardiac and hepatic tissue in the same way.
Separate clinical evidence already exists showing that semaglutide reduces symptoms and hospitalizations in people with HFpEF who also have obesity, but that evidence does not isolate weight-loss-independent effects. This study was designed specifically to probe that gap, and it does so only in animals.
The open question, and it is a significant one, is whether a human trial could be designed to test the same thing: semaglutide at doses below those that cause meaningful weight loss, in people with established HFpEF, with cardiac MRI and tissue-level endpoints. That trial does not yet exist, as far as this report indicates. Until it does, the mechanism suggested here remains preclinical. Anyone weighing a GLP-1 drug for cardiac reasons should have that conversation with a clinician who knows their full history.